A biologic developer with an autoinjector needed clarity across CDER and CDRH. Pharmatech resolved classification ambiguities, led agency discussions, and mapped a dual pathway strategy.
Impact for the client:
- Regulatory alignment achieved across CDER and CDRH
- BLA and 510(k) submissions streamlined
- Approval timelines reduced by six months
